Limited value of acyclovir in the treatment of uncomplicated herpes zoster by Broek, P.J. van den et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
This full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/14766
 
 
 
Please be advised that this information was generated on 2014-11-11 and may be subject to
change.
O rig in a lia
P. J. van den Broek, J. W. M. van der Meer, J. D. Mulder, J. Versteeg, H. Mattie
Limited Value of Acyclovir in the Treatment of Uncomplicated Herpes 
Zoster: A Placebo-controlled Study
Summary: The effect of intravenous acyclovir (at a 
dosage of 30 mg/kg per day for five days) on uncompli­
cated herpes zoster was investigated in 51 patients in a 
double-blind study. Although existing herpes zoster le­
sions tended to heal more rapidly and new lesions cea­
sed to appear somewhat earlier in the acyclovir group, 
these differences were not statistically significant. Du­
ring treatm ent, patients on acyclovir had significantly 
lower pain scores than placebo-treated patients. At 
follow-up, however, there was no difference between 
the two groups. Complications of herpes zoster occur­
red only in the placebo groups (generalization in two 
and keratitis in two cases). With the possible exception 
of trigeminal zoster or severe pain, acyclovir seems to 
offer little benefit for immunocompetent patients with 
herpes zoster.
Zusammenfassung: Begrenzter Wert von Acyclovir in 
der Therapie des unkomplizierten Herpes zoster: Eine 
Plazebo-kontrollierte Studie. Die Wirkung von Acyclo­
vir intravenös (in einer Dosis von 30 mg/kg pro Tag für 
fünf Tage) auf den unkomplizierten Herpes zoster 
wurde bei 51 Patienten in einer Doppelblindstudie 
geprüft. Obwohl bei den vorhandenen Herpes zoster- 
Läsionen eine Tendenz zu rascherer Heilung bestand 
und das Neuauftreten von Läsionen in der Acyclovir- 
Gruppe etwas früher aufhörte, waren diese U nter­
schiede statistisch nicht signifikant. U nter der Behand­
lung war die Schmerz-Score bei Patienten, die Acyclo­
vir erhielten, signifikant niedriger als bei Patienten, 
die Placebo erhielten. Bei der Verlaufsbeurteilung fan­
den sich zwischen den Gruppen jedoch keine U nter­
schiede. Zu Komplikationen des Herpes zoster kam es 
nur in der Plazebo-Gruppe (in je zwei Fällen G enera­
lisation und Keratitis). Mit der möglichen Ausnahme 
des Zoster im Trigeminus-Bereich oder starker 
Schmerzen scheint Acyclovir bei immunkompetenten 
Patienten mit Herpes zoster nur von geringem Wert zu 
sein.
Introduction
Acyclovir is a new antiviral drug with activity against Va­
ricella zoster virus in vitro (1). In the present study, the 
value of acyclovir in the treatm ent of uncomplicated her­
pes zoster was assessed.
Patients and Methods
In the period from  January  1981 to January  1983, all patients 
with a clinical diagnosis of shingles who presented  w ithin 72 
hours after the onset of the rash w ere en te red  into the study. Ex­
clusion was made for neurologic or o cu la r com plications o f her­
pes zoster, granulocyte counts below 0.1 x  109/l, chem otherapy 
for cancer and pregnancy. A fter inform ed consent was ob ta in ­
ed, the patients were random ly allocated to receive e ith e r acy­
clovir 10 mg/kg ( -  0.4 ml/kg) or p lacebo (0.4 ml/kg) a t eight 
hour intervals, 15 doses in all. In the first nine patients the  drug 
or placebo was adm inistered by intravenous injection, but when 
it becam e known that the  adm inistration of acyclovir in this way 
led to phlebitis and elevation of serum  creatinine (2), the requir­
ed dose was diluted in a volume of at least 100 ml and given over 
30-60 min as side-infusion to a rapidly flowing (about 250 ml in 
60 min) infusion of saline or 5% glucose. If necessary, the  dose 
was adjusted  to renal function according to the schem e propos­
ed  by Blum  et al. (3). No further trea tm en t for herpes zoster was 
given. Analgesics (initially paracetam ol) were prescribed when 
the patients asked for pain relief. The presence o r absence of pa­
pules, pustules, ulcerations, crusts or healed lesions, fever, pain 
(scored as none, slight, m oderate or severe by questioning the 
patien t), change of pain (scored as increased, unchanged o r de­
creased) and use of analgesics were recorded  daily during  the 
course of the trea tm en t, and approxim ately ten  days after term i­
nation  of the trea tm en t,by  one of us who was unaw are o f the 
random ization code. H em oglobin, leukocytes and p latelets, as 
well as liver enzymes and serum creatin ine, w ere checked be­
fore, during and after treatm ent.
Virology: Swabs from skin lesions w ere taken from all patients 
for viral culture. For transport the specim ens w ere held in Gly 
medium and then cultured by inoculation onto hum an fetal di­
ploid fibroblasts. The presence of antibodies to herpes zoster vi­
rus in serum  was dem onstrated  w ith an im m une adherence 
hem agglutination test (4).
Statistical analysis: W ilcoxon’s tw o-sam ple test was used for the 
statistical analysis. Skin lesions, pain score and analgesic use in 
the two groups were com pared by com puting the areas under 
the curves.
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Table 1: Characteristics of the patients.
Placebo Acyclovir
N um ber of patients 24 26
Male 12 16
Female 12 11
Age (m edian [range]) 69 (20-89) 59 (12-87)
Underlying disease 1* 4**
D uration of sym ptom s
until onset o f  rash 50 (1-120) 23 (0-120)
(hours; m edian [range])
Time betw een onset of
rash and s ta rt o f therapy 36 (12-72) 25 (6-72)
(hours; m edian [range])
* Renal transp lan t;
** Two cases o f  renal transplantation , one of cured  H odgkin’s 
disease and one of chronic lym phatic leukaem ia.
Results
F ifty -one  p a t ie n ts  w e re  e n ro l le d  in  th e  s tu d y . F o rty -tw o  
o f  th ese  p a t ie n ts  w e re  re f e rre d  by  th e ir  g e n e ra l p rac tio n -
er. All but two of the patients were examined by one of 
the two physicians who conducted this clinical trial. One 
patient was not evaluable due to lack of follow-up data, 
and all but one of the patients were hospitalized. Placebo 
was given to 24 and acyclovir to 26 patients. There were 
no statistically significant differences as to sex, age, un­
derlying disease duration of symptoms, or time elapsed 
between the onset of the rash and the start of treatment 
(Table 1), although the patients in the acyclovir group 
had a shorter duration of complaints than those in the pla­
cebo group. On entry into the trial, the localization and 
extension of the rash, pain score and use of analgesics did 
not differ significantly. However, the higher number of 
patients with trigeminal zoster in the acyclovir group may 
be important. Comparison of the patients with trigeminal 
zoster with the other patients, regardless of treatment 
group, showed that the former had less pain on Day 4 
(p = 0.04), the papules disappeared earlier (p = 0.002) 
and crust formation and healing were faster (p = 0.02). 
This accelerated recovery in trigeminal zoster patients 
was previously described by Wildenhoff et al. (5).
The evolution of the skin lesions did not differ greatly be-
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Figure 1: Evolution of the skin lesions
in the patients on acyclovir (-----) and
in the placebo group (------). The per­
centage of patients with the indicated 
lesion is shown on the y axis.
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Table 2: State of the disease at enrollment in the trial.
Number of patients 
Placebo Acyclovir
Localization
Trigeminal nerve 5 10
Cervical 7 Í
Thoracic 10 12
Lumbar 2 2
Sacral 0 1
Extension of the disease
Scanty discrete 2 6
Profuse discrete 3 1
Semi-confluent 15 17
Confluent 4 2
Pain
None 7 10
Slight 5 8
Moderate 7 4
Severe 5 4
Use of analgesics 5 4
Fever (>  37.5° C) 14 13
tween the acyclovir and placebo groups (Figure 1). Papul­
es regressed at the same rate; pustules and ulcerations dis­
appeared more rapidly in the acyclovir group, but this dif­
ference was not statistically significant. Crusts appeared 
and lesions healed at the same time in both groups. New 
lesions ceased to appear earlier in the acyclovir group: on 
the mean, no new lesions were observed after 2.77 days 
(SD = 0.99) in the acyclovir-treated patients and 3.42 
days (SD = 1.32) in the placebo-treated patients 
(P = 0.13).
Patients on acyclovir had a significantly lower mean pain 
score than patients receiving placebo (Figure 2A)
(p = 0.05). The difference was most marked on Days 3 ,4  
and 5. This finding corresponds with a larger proportion 
of patients already indicating decrease of pain already on 
Day 2 in the acyclovir group (Figure 2B), but after about 
the tenth day after termination of the treatm ent, there 
was no difference. Correspondingly, less analgesics were 
used in the acyclovir group (Figure 2C; p = 0.06). 
Complications of herpes zoster occurred only in the place­
bo group and concerned two patients with keratitis, which 
is a complication of trigeminal zoster, and two patients 
with generalization of the herpes zoster to o ther skin 
areas. Thus, two of the five patients who had trigeminal 
zoster and were on placebo developed keratitis as oppos­
ed to none of ten patients with trigeminal zoster on acy­
clovir (p = 0.19) (Fisher’s exact test).
Serious side-effects of treatment were not encountered: 
phlebitis at the infusion site was seen in three acyclovir 
and four placebo recipients. All three cases of phlebitis 
occurred in the period during which acyclovir was given as 
intravenous injection. No differences were observed in 
either group as to changes in the serum creatinine level 
during the administration of acyclovir or placebo.
There was no doubt concerning the diagnosis of herpes 
zoster in any of the patients. The clinical diagnosis was 
confirmed in nine patients by both serology (four-fold rise 
in titer) and culture, in 25 by serology and in two by cul­
ture alone. In nine patients the diagnosis was not confirm­
ed by either of these methods, and for five patients such 
data were lacking. No effect of acyclovir on antibody re­
sponse was found.
Discussion
In this study, slight and statistically non-significant differ­
ences in the evolution of the skin lesions were found be­
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Figure 2: Mean pain score (A), per­
centage of patients reporting a de­
crease or increase of pain (B) and 
percentage of patients using analges­
ics (C) for the acyclovir-treated pa­
tients (—  and g§]) and placebo-treat­
ed patients (------ and Q).
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tween (he acyclovir group and the placebo group. The ap­
pearance of new lesions ceased on average 15 hours earli- 
eT in the acyclovir than in the placebo group, and regres­
sion of the skin lesions was seen at an earlier stage in the 
acyclovir group.
A significant but transient decrease in pain during treat­
ment with acyclovir was seen, but after treatment there 
was no difference between the two groups. The somewhat 
earlier entrance into the study of the patients alotted to 
the acyclovir treatm ent can be a disadvantage for acyclo­
vir: the patients have not yet reached the height of the dis­
ease. in contrast to the patients in the placebo group. On 
the other hand, the higher incidence of rapidly healing 
ophthalmic zoster (5) and the somewhat lower age in the 
acyclovir group could have had a favourable impact on 
healing in this group.
Complications accompanying herpes zoster only occurred 
in the placebo group. Generalization, which is not a se­
vere complication in immunocompetent patients, was 
seen twice. The severe complication, keratitis, was also 
seen twice. This complication did not occur in the acyclo­
vir group despite the relatively large number of patients 
with trigeminal zoster in this group. Juel-Jensen et al. (6), 
using the same dose of acyclovir, also observed that none 
of their patients with ophthalmic zoster and on acyclovir 
developed complications, whereas three of the four pa­
tients on placebo developed complications.
The side-effects of acyclovir were minimal in the present 
series; we did not encounter the high incidence of renal
toxicity reported by Bean et al. (7), who used the same in­
travenous dose of acyclovir.
The results of the present study are less favourable than 
those reported by Peterslund (8), who used a dose of 15 
mg/kg per day in a series of 56 patients and reported more 
rapid healing of skin lesions and less pain. Bean et al. (7) 
made similar findings in a smaller group of patients (19 on 
acyclovir, ten on placebo) treated with a high dose of acy­
clovir (500 mg/m2). Like us, these authors saw recurrence 
of pain after acyclovir was discontinued. In a study com­
prising 37 patients, McGill et al. (9) found accelerated 
healing of skin lesions in acyclovir-treated patients (15 
mg/kg/day) but no statistically significant effect on the 
pain during the acute phase of the disease or at three 
months.
In view of the small differences found in our study and in 
the published series (6-9), we conclude that except per­
haps in patients with trigeminal zoster or severe pain, acy­
clovir offers minimal benefit, even when administered in­
travenously to immunocompetent patients.
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